Clinical trial
Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atrial Fibrillation and Rapid Ventricular Rate (RVR)
NCT06716021 is registered in ClinicalTrials.gov with Milestone Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atrial Fibrillation and Rapid Ventricular Rate (RVR)
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 20, 2026
- Completion date
- December 31, 2029
- Enrollment
- 750 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.